12,372 trials
Breast Cancer
Primary: Progression-free Survival (PFS) Per Investigators' Assessment Based on Local Radiology Review - Full Population — 14.95; 14.49 months — p=0.1166
Type 1 Diabetes
Primary: Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c. — 9.0; 8.9; 0.2; 0.2 percentage
Tardive Dyskinesia
Primary: Number of Participants Monitored for Long-term Safety of Valbenazine — 35; 117; 8 Participants
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 18.14; NA Months
ICU Sedation
Primary: Percentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug — 78.6; 66.7; 78.9; 91.7 percentage of participants
Infections, Papillomavirus
Primary: Number of Subjects Reporting Any, Grade 3 and Related Serious Adverse Events (SAEs) — 1; 1; 0 Participants
Infections, Streptococcal
Primary: Number of Subjects With Core Fever (Rectal Temperature) Greater Than (>) the Cut-off — 5; 2; 1; 1 Participants
Delayed Graft Function
Primary: Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplant — 35.9; 41.7; 33.8; 39.6 percentage of participants — p=0.3983
Major Depressive Disorder
Primary: Incidence of Adverse Events (AEs) — 1124 Participants
Keratoconjunctivitis Sicca
Primary: Adverse Events — 68; 81 Count of participants
Acromegaly
Primary: Standardised Mean Change From Baseline in Age-adjusted IGF-1 Levels at the EOST/EW Visit — -0.84; -0.52; 0.43; 0.59 SDS
Infections, Streptococcal
Primary: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary…
Pain
Primary: Postoperative Pain — 30; 45 scores on a scale*minutes
Influenza
Primary: Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo — 53.7; 80.2 hours — p=<0.0001
Keratoconjunctivitis Sicca · Dry Eye Disease
Primary: Conjunctival Staining — -1.9; -1.8; -1.2 score on a scale